PE20010685A1 - Composicion que comprende un polipeptido antagonista del receptor de interleuquina 1 y una diarilsulfonilurea como inhibidor del procesamiento y la liberacion de il-1 - Google Patents
Composicion que comprende un polipeptido antagonista del receptor de interleuquina 1 y una diarilsulfonilurea como inhibidor del procesamiento y la liberacion de il-1Info
- Publication number
- PE20010685A1 PE20010685A1 PE2000000942A PE0009422000A PE20010685A1 PE 20010685 A1 PE20010685 A1 PE 20010685A1 PE 2000000942 A PE2000000942 A PE 2000000942A PE 0009422000 A PE0009422000 A PE 0009422000A PE 20010685 A1 PE20010685 A1 PE 20010685A1
- Authority
- PE
- Peru
- Prior art keywords
- interleuquin
- release
- processing
- urea
- hydroxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A USO DE UNA COMPOSICION QUE COMPRENDE: a)UN POLIPEPTIDO ANTAGONISTA DEL RECEPTOR DE INTERLEUQUINA 1 (IL-1ra), DE PREFERENCIA DE UNA SECUENCIA (ID SEQ N°2) DE 169 AMINOACIDOS; b)UN AGENTE NO ESTEROIDEO QUE INHIBE EL PROCESAMIENTO Y LA LIBERACION DE IL-1 TAL COMO DIARILSULFONILUREA R1-(O=)S(=O)-NH-C(=O)-NH-R2; DONDE R1 Y R2 SON UN GRUPO DE FORMULA II EN LA QUE LAS LINEAS --- REPRESENTAN DOBLES ENLACES OPCIONALES; n ES 0-3; A, B, D, E Y G SON O, S, N, CR5R6; R5 Y R6 SON H, ALQUILO C1-C6, HALOGENO, CIANO, AMINO, OH, ENTRE OTROS, SIENDO COMPUESTOS SELECCIONADOS 1-(1,2,3,5,6,7-HEXAHIDRO-s-INDACEN-4-IL)-3-[4-(1-HIDROXI-1-METIL-ETIL)-FURANO-2-SULFONIL]-UREA, 1-(2,6-DIISOPROPIL-FENIL)-3-[4-(1-HIDROXI-1-METIL-ETIL-FURANO-2-SULFONIL]-UREA, 1-(4-CLORO-2,6-DIISOPROPIL-FENIL)-3-[3-(HIDROXI-1-METIL-ETIL)-BENCENOSULFONIL]-UREA, ENTRE OTROS. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE TRASTORNOS INFLAMATORIOS TAL COMO ARTRITIS REUMATOIDE, OSTEOARTRITIS, ASMA, NEURODEGENERACION, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15401099P | 1999-09-14 | 1999-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010685A1 true PE20010685A1 (es) | 2001-07-03 |
Family
ID=22549650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000942A PE20010685A1 (es) | 1999-09-14 | 2000-09-12 | Composicion que comprende un polipeptido antagonista del receptor de interleuquina 1 y una diarilsulfonilurea como inhibidor del procesamiento y la liberacion de il-1 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1214087A1 (es) |
| JP (1) | JP2003509378A (es) |
| AR (1) | AR033650A1 (es) |
| AU (1) | AU6464400A (es) |
| BR (1) | BR0014003A (es) |
| CA (1) | CA2383026A1 (es) |
| CO (1) | CO5190701A1 (es) |
| EC (1) | ECSP003652A (es) |
| GT (1) | GT200000155A (es) |
| PA (1) | PA8502901A1 (es) |
| PE (1) | PE20010685A1 (es) |
| TN (1) | TNSN00183A1 (es) |
| WO (1) | WO2001019390A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1729810T3 (en) | 2004-04-02 | 2018-12-03 | Swedish Orphan Biovitrum Ab Publ | PROCEDURE FOR REDUCING AGGREGATION OF IL-1RA |
| WO2008129288A2 (en) * | 2007-04-19 | 2008-10-30 | Boehringer Ingelheim International Gmbh | Disulfonamides useful in the treatment of inflammation |
| CN113582889A (zh) * | 2015-02-16 | 2021-11-02 | 昆士兰大学 | 磺酰脲和相关化合物及其用途 |
| CA3014487A1 (en) | 2016-02-16 | 2017-08-24 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Sulfonylureas and related compounds and use of same |
| ES2927777T3 (es) | 2016-04-18 | 2022-11-10 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| MA47308A (fr) | 2017-01-23 | 2019-11-27 | Genentech Inc | Composés chimiques comme inhibiteurs de l'activité interleukine-1 |
| CA3059458A1 (en) | 2017-05-24 | 2018-11-29 | The University Of Queensland | Novel compounds and uses |
| US11236045B2 (en) | 2017-06-09 | 2022-02-01 | Cadila Healthcare Limited | Substituted sulfoximine compounds |
| PE20212077A1 (es) | 2017-07-07 | 2021-10-28 | Inflazome Ltd | Nuevos compuestos sulfonamida de carboxamida |
| US11370776B2 (en) | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| RS65492B1 (sr) | 2017-07-24 | 2024-05-31 | Novartis Ag | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp |
| PE20200758A1 (es) * | 2017-08-15 | 2020-07-27 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3 |
| EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| US11773058B2 (en) | 2017-08-15 | 2023-10-03 | Inflazome Limited | Sulfonamide carboxamide compounds |
| US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| EP3692020A1 (en) | 2017-10-03 | 2020-08-12 | Inflazome Limited | Novel compounds |
| MA50567A (fr) | 2017-11-09 | 2020-09-16 | Inflazome Ltd | Nouveaux composés de sulfonamide carboxamide |
| EP3759103A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| EP3759078A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| US11834433B2 (en) | 2018-03-02 | 2023-12-05 | Inflazome Limited | Compounds |
| GB201806578D0 (en) * | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| CN112584899A (zh) | 2018-07-03 | 2021-03-30 | 诺华股份有限公司 | Nlrp调节剂 |
| MA53170A (fr) | 2018-07-20 | 2021-05-26 | F Hoffmann La Roche Sa | Composés de sulfonylurée en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| US20230011652A1 (en) | 2018-10-24 | 2023-01-12 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| JP7488267B2 (ja) | 2019-01-14 | 2024-05-21 | ザイダス・ライフサイエンシーズ・リミテッド | 新規な置換スルホニル尿素誘導体 |
| CN111875694B (zh) * | 2020-05-25 | 2022-07-05 | 北京伟德杰生物科技有限公司 | 一种白细胞介素-1受体拮抗剂以及包含其的融合蛋白 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874424A (en) * | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| PL335052A1 (en) * | 1997-01-29 | 2000-03-27 | Pfizer | Derivatives of sulphonylurea and their application in regulating activity of interleukin-1 |
| US6015790A (en) * | 1997-10-06 | 2000-01-18 | Basf Aktiengesellschaft | Methods and compositions for treating rheumatoid arthritis |
| EP0987552A3 (en) * | 1998-08-31 | 2000-06-07 | Pfizer Products Inc. | Diarylsulfonylurea binding proteins |
-
2000
- 2000-08-28 AU AU64644/00A patent/AU6464400A/en not_active Abandoned
- 2000-08-28 EP EP00951799A patent/EP1214087A1/en not_active Withdrawn
- 2000-08-28 CA CA002383026A patent/CA2383026A1/en not_active Abandoned
- 2000-08-28 JP JP2001523022A patent/JP2003509378A/ja active Pending
- 2000-08-28 BR BR0014003-1A patent/BR0014003A/pt not_active IP Right Cessation
- 2000-08-28 WO PCT/IB2000/001192 patent/WO2001019390A1/en not_active Application Discontinuation
- 2000-09-05 CO CO00066883A patent/CO5190701A1/es not_active Application Discontinuation
- 2000-09-11 PA PA20008502901A patent/PA8502901A1/es unknown
- 2000-09-12 PE PE2000000942A patent/PE20010685A1/es not_active Application Discontinuation
- 2000-09-12 EC EC2000003652A patent/ECSP003652A/es unknown
- 2000-09-12 AR ARP000104779A patent/AR033650A1/es not_active Application Discontinuation
- 2000-09-13 TN TNTNSN00183A patent/TNSN00183A1/fr unknown
- 2000-09-14 GT GT200000155A patent/GT200000155A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU6464400A (en) | 2001-04-17 |
| CA2383026A1 (en) | 2001-03-22 |
| BR0014003A (pt) | 2002-05-21 |
| PA8502901A1 (es) | 2002-02-21 |
| WO2001019390A1 (en) | 2001-03-22 |
| JP2003509378A (ja) | 2003-03-11 |
| GT200000155A (es) | 2002-03-08 |
| CO5190701A1 (es) | 2002-08-29 |
| ECSP003652A (es) | 2002-04-23 |
| EP1214087A1 (en) | 2002-06-19 |
| AR033650A1 (es) | 2004-01-07 |
| TNSN00183A1 (fr) | 2005-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010685A1 (es) | Composicion que comprende un polipeptido antagonista del receptor de interleuquina 1 y una diarilsulfonilurea como inhibidor del procesamiento y la liberacion de il-1 | |
| PE20040840A1 (es) | Derivados de 4-oxoquinolina como inhibidores de la integrasa del vih | |
| HRP941000B9 (hr) | Morfolin i tiomorfolin antagonisti receptora tahikinina | |
| ES2161231T3 (es) | Compuestos heterociclicos como antagonistas de bradiquinina. | |
| PE20060298A1 (es) | Derivados de acido carboxilico de bencimidazolona | |
| ATE420644T1 (de) | Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1) | |
| PT1716152E (pt) | Compostos heterocíclicos fundidos e sua utilização como antagonistas do receptor metabotrópico para o tratamento de distúrbios gastrointestinais | |
| ATE469892T1 (de) | Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung | |
| BR0307833A (pt) | Sìntese controlada de ziprasidona e suas composições | |
| UY27976A1 (es) | Piperazinas heterocíclicas sustituídas para el tratamiento de la esquizofrenia | |
| NO20063470L (no) | Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister | |
| PE20040650A1 (es) | Moduladores del receptor de glucocorticoides | |
| BRPI0413305A (pt) | compostos azabicìclicos fundidos que inibem o receptor de subtipo de receptor de vanilóide 1 (vr1) | |
| DE602006007556D1 (de) | Heteroarylsulfonylstilbene als 5-ht2a-antagonisten | |
| NO20051102L (no) | Sulfonylamino-eddiksyre-derivater | |
| BR0007595A (pt) | 4-(heterociclisulfonamido)-5-metóxi-6-(2-metoxifenó xi)-2-fenil-ou piridilpirimidinas como antagonistas de receptor de endotelina | |
| AR028824A1 (es) | Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos. | |
| ES2192264T3 (es) | Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2(1h)-indol-2-ona (=ziprasidona), su preparacion y su uso como antagonista de la dopamina. | |
| UY28150A1 (es) | Agentes terapeuticos | |
| IS8377A (is) | Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns | |
| PE20030872A1 (es) | Composicion farmaceutica del agonista parcial de 5ht4 tegaserod | |
| ATE374190T1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| WO2007073303A3 (en) | Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors | |
| PE16299A1 (es) | Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptores | |
| NO20080323L (no) | Forbindelser og deres salter som er spesifikke overfor PPAR-reseptorer og EGF-reseptorer og deres anvendlse innen medisinen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |